Sacituzumab Govitecan + Bevacizumab for Ovarian Cancer

This trial tests a new treatment for ovarian cancer that has returned after initial treatment and exhibits specific genetic markers (BRCA1/2 mutations or homologous recombination deficiency). The study compares two treatments: a combination of sacituzumab govitecan, a targeted therapy that delivers cancer-killing drugs directly to cancer cells, and bevacizumab, which prevents tumor growth by cutting off its blood supply, against the current standard treatment. The researchers aim to determine if the new combination can kill more cancer cells than the usual treatment. This trial may suit those with ovarian cancer that responded to platinum therapy but progressed after PARP inhibitor maintenance and have the specified genetic profile. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that you stop any current treatment with cytotoxic chemotherapy, targeted therapy, biologic therapy, immunotherapy, or endocrine therapy for your ovarian cancer. Additionally, you must not have taken any investigational agents within 4 weeks before joining the study.

Previous studies found that sacituzumab govitecan was generally well-tolerated by patients. Common side effects included low levels of a type of white blood cell, nausea, diarrhea, and tiredness, occurring in more than 60% of patients. Despite these side effects, many patients continued treatment, suggesting they may be manageable.

Bevacizumab, another treatment in this trial, is already approved for other types of cancer, so its safety is well-known. Typical side effects include high blood pressure and bleeding, which can be managed with medical care.

Researchers are excited about Sacituzumab Govitecan for ovarian cancer because it introduces a novel approach by combining a targeted antibody with a cancer-killing drug. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, Sacituzumab Govitecan specifically targets cancer cells by attaching to a protein called Trop-2, which is often overexpressed in ovarian cancer cells. This targeted mechanism could potentially lead to fewer side effects and more effective tumor reduction. Additionally, combining it with Bevacizumab, an anti-VEGF therapy, may enhance its effectiveness by inhibiting blood supply to the tumor, making it a promising option for patients who haven't responded to standard treatments.

This trial will compare two treatment regimens for ovarian cancer. In one arm, patients will receive a combination of carboplatin, pegylated liposomal doxorubicin hydrochloride (PLD), and bevacizumab. Studies have shown that adding bevacizumab to chemotherapy can extend the time patients with ovarian cancer live without disease progression. Specifically, one study found that patients receiving bevacizumab with chemotherapy had a median progression-free survival of 6.7 months, compared to 3 months for those receiving only chemotherapy.